MedDataX Logo

Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre

NCT ID: NCT03993093

Last Updated: 2020-03-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

257 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-06-01

Study Completion Date

2020-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

HIV patients are likely to suffer from opportunistic infections, in absence of highly active retroviral therapy. This happens due to lack of awareness of HIV status among patients or unresponsive to anti retroviral drugs. This study is for the prevalence of AIDS defining OIs among treatment naive HIV patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of the Long-Term Outcomes of HIV-Positive Patients

NCT00000932

HIV Infections
COMPLETED

Examining Factors That May Influence Resistance to HIV-1 Infection

NCT00351442

HIV Infections
COMPLETED

Understanding HIV Susceptibility in the Female Genital Tract

NCT03064425

HIV Infections
COMPLETED

Long Term Follow-Up of HIV Infected Patients Who Have Previously Participated in HIV Clinical Trials

NCT00183287

HIV Infections
COMPLETED

A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection

NCT00005572

Cytomegalovirus Infections Cytomegalovirus Retinitis Pneumonia, Pneumocystis Carinii +1 more
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Oppotunistic infections (OIs) happen in persons with weakened immune system. HIV patients, who remain untreated due to lack of knowledge of existing HIV infections, often get OIs. HIV patients with AIDS defining OIs fall into stage 3 of HIV illness. Prevalence of OIs in resource poor settings are tuberculosis (pulmonary and extra pulmonary), toxoplasmosis, cryptococcosis, and oesophageal candidiasis. There are a few data to show AIDS defining OIs in treatment naïve HIV patients. Incidence of OIs among HIV patients in United States, and Canada between 2000 to 2019 was 9%. Leading OIs were peumocystis Jiroveci, oesophageal candidiasis and disseminated MAC or M. kansassi.

Minimal diagnoses at poor settings can be made by observation of symptoms, use of microscope, imaging and diagnostic therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Tuberculosis Candidiasis, Esophageal Cryptococcosis Leishmaniasis Toxoplasmosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV with OIs

Treatment naive HIV patients with OIs

CD4 cell count

Intervention Type OTHER

CD4 cell count from treatment naive HIV patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CD4 cell count

CD4 cell count from treatment naive HIV patients

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• HAART naïve HIV patient

Exclusion Criteria

* Patients died during screening
* Transferred in HIV patients
Minimum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Singh, Ranjan Kumar, M.D.

INDIV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ranjan Kumar Singh

Physician, cum nodal officer, ART centre Khagaria

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ranjan K Singh, M.D.

Role: PRINCIPAL_INVESTIGATOR

Singh, Ranjan Kumar

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ART centre, Sadar Hospital

Khagaria, Bihar, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SinghRK1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COVID-19 in Patients With HIV
NCT04333953 COMPLETED
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection
NCT00789009 RECRUITING
Observing Patients With Early HIV Infection
NCT00005020 COMPLETED
HIV Patients Cohort
NCT02203006 ACTIVE_NOT_RECRUITING NA
Problems With Immune Recovery in the Gut Tissue
NCT01460433 COMPLETED
A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of HIV/AIDS Complicated With Infection
NCT06280001 NOT_YET_RECRUITING
HIV and Changes in the Gut Microbiome After Changes in Antiretroviral Therapy (ART)
NCT06100211 RECRUITING
Outcomes of Anti-HIV Therapy During Early HIV Infection
NCT00001093 COMPLETED
HIV Assessment in Fuyang, Anhui Province, China
NCT00094354 COMPLETED
Pilot Study of Immediate HIV Treatment in Guangxi, China
NCT01892228 UNKNOWN NA
Gut Microbiota Changes of HIV Patients Before and After One Year of ART
NCT04297501 COMPLETED
Long-term Follow-up of HIV Infected Patients Identified During Early Infection
NCT00086372 COMPLETED
Analysis of HIV-1 Replication During Antiretroviral Therapy
NCT00767312 ENROLLING_BY_INVITATION
Gut Associated Lymphatic Tissue (GALT) in HIV (Human Immunodeficiency Virus)- Infected Patients
NCT01679067 COMPLETED
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
NCT07146529 NOT_YET_RECRUITING
A Study of Immune System Activity in Healthy Adults
NCT00014053 COMPLETED
Treatment of Acute HIV Infection to Preserve Immune Function
NCT00055094 COMPLETED
Evaluation of HIV-1 Recent Infection Testing in Rwanda
NCT05063487 COMPLETED
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials
NCT03337906 COMPLETED
Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment
NCT02334943 COMPLETED NA
Clinical Epidemiology Cohort Study for Patient Living With HIV
NCT04061889 UNKNOWN
Observational PIC Destination Cohort
NCT05985642 RECRUITING
Auditory Research in Children Living With HIV Exposure-uninfected (ARCHIVE)
NCT06635642 NOT_YET_RECRUITING NA
Immunologic Control of Drug Resistant HIV
NCT00053404 UNKNOWN
A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1
NCT00001121 COMPLETED